FDA Panel Rejects Guerbet’s Imaging Drug Dotarem For Young Children
This article was originally published in The Pink Sheet Daily
Executive Summary
The gadolinium-based contrast agent should be approved for use in adults and older pediatric patients, but more data are needed to support a novel indication for children under two years old, the Medical Imaging Drugs Advisory Committee says.